Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601206 | 0.85 | TDP1 (0.35) | — | |
| SCHEMBL20015198 | 0.81 | MAPK1 (0.32) | — | |
| SCHEMBL2601283 | 0.80 | NOX4 (0.37) | — | |
| SCHEMBL2601289 | 0.77 | KDM4E (0.39) | — | |
| SCHEMBL2601134 | 0.75 | MAPT (0.38) | — | |
| SCHEMBL15148486 | 0.73 | AGTR1 (0.37) | LIPG | |
| SCHEMBL20829676 | 0.72 | ABCB11 (0.42) | — | |
| SCHEMBL24834255 | 0.72 | ALDH1A1 (0.40) | — | |
| SCHEMBL24834251 | 0.71 | KDM4E (0.48) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL20123363 | 0.70 | MAPT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2444400-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9758515-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| EP-2620436-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | Shionogi&Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2444400-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147068-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | 塩野義製薬株式会社 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | LIPG 1843/4885MMP1 472/4885MMP7 512/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | LIPG 1843/4885MMP1 472/4885MMP7 512/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | LIPG 1983/4885MMP1 209/4885MMP7 312/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | LIPG 1983/4885MMP1 209/4885MMP7 312/4885 |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | LIPG 1983/4885MMP1 209/4885MMP7 312/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | LIPG 1972/4885MMP1 200/4885MMP7 292/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | LIPG 1983/4885MMP1 209/4885MMP7 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.